氟苯尼考PEG6000固体分散体在大鼠体内的生物利用度研究

目的]研究氟苯尼考PEG6000固体分散体在大鼠体内的生物利用度.方法]建立大鼠血浆中氟苯尼考的HPLC检测方法.用灌喂药物水溶液的方法,通过高效液相分析技术对氟苯尼考PEG6000固体分散体的血药浓度进行测定,与氟苯尼考原粉进行对照.结果]氟苯尼考PEG6000固体分散体在大鼠体内吸收及代谢良好,氟苯尼考固体分散体和氟苯尼考原药的最高血药浓度分别为13.44和3.88 μ.g/ml,提高了3.46倍;药-时曲线下面积分别为：氟苯尼考原粉AUC0-8h=20.12 25 μg/（ml·h）、氟苯尼考固体分散体AUC0-8h=23.22μg/（ml·h）,氟苯尼考-PEG6000固体分散体口服生物利用度与氟苯尼考原粉相比提高了15.39％.结论]氟苯尼考-PEG6000固体分散体能显著提高氟苯尼考的生物利用度.

Bioavailability Study of Florfenicol-Polyethyleneglycol 6000 Solid Dispersion in Rats

Objective] To study the bioavailability of florfenicol-polyethyleneglycol 6000 solid dispersion in rats. Method ] Set up a HPLC method for florfenicol in rat plasma. The plasma concentration of florfenicol- polyethyleneglycol 6000 solid dispersion is tested by HPLC analysis after being fed with drug solution, and is compared with that of raw florfenicol. Result] The absorption and metabolism of florfenicol- polyethyleneglycol 6000 solid dispersion are good in rats. The maximum plasma concentration of florfenicolpolyethyleneglycol 6000 solid dispersion and raw florfenicol are 13.44 and 3.88 μg/ml, respectively. The former is increased by 3.46 times ; The condition of AUC ： raw florfenicol ： AUC0-8 h = 20. 122 5 μg/（ ml . h） ; florfenicol- polyethyleneglycol-6000 solid dispersion： AUC0-8h = 23.22 μg/（ ml . h）. Compared with raw florfenicol ,the oral bioavailability of florfenicol-polyethyleneglycol-6000 solid dispersion increased by 15.39%. Conclusion] Florfenicol-polyethyleneglycol-6000 solid dispersion can significantly increase the bioavailability of florfenicol.